Articles

Acceleron and Westlake Launch New IPF Biotech Venture

Acceleron and Westlake are initiating a new biotech focused on idiopathic pulmonary fibrosis (IPF). This article explores the implications for the pharmaceutical industry.

Gilead's $140M Deal with Yuhan: Implications for Pharma

Gilead Sciences has signed a significant $140M deal with Korean API manufacturer Yuhan. This article explores the implications for the pharmaceutical landscape.

Drugmakers Tighten IP Protections Amid China Competition

As competition from China intensifies, drugmakers are increasingly safeguarding their intellectual property. This article explores the implications for the pharmaceutical industry.

White House Expands TrumpRx Portal with 600 Generic Meds

The White House has added 600 generic medications to the TrumpRx purchasing portal, impacting pharma pricing and access. This article explores the implications for the industry.

Navigating the Data: B2B Event Coverage 2026

Join us as we preview the Navigating the Data event in Boston. Learn about key companies to watch and the catalysts that could impact the market.

ReDI 2026 Conference: Key Insights for B2B Readers

The ReDI 2026 Conference promises to be a pivotal event for B2B stakeholders in the pharma industry. Here’s what you need to know ahead of the conference.

Migraine Drugmaker Goes Public: Insights on Reverse Merger

A migraine drugmaker is set to enter public markets via a reverse merger, raising questions about its future impact on the pharmaceutical landscape.

Roche's Licensing Deal for Generic Xofluza: Implications and Insights

Roche has signed a licensing deal for generic Xofluza with the Medicines Patent Pool, impacting 129 countries. This article explores the implications for pharma teams and investors.

CG Life's Strategic Leadership Move: Collette Douaihy as CCO

CG Life has appointed Collette Douaihy as Chief Creative Officer, marking a significant step in its C-suite expansion. This article explores the implications for the pharmaceutical sector.

STAT+: Pioneering Trial for Treating Genetic Disease Before Birth

This article discusses the upcoming FDA trial for in-utero gene therapy targeting genetic diseases, highlighting its significance for the pharmaceutical industry.

Oorja Launches New Fibrosis Drug Development Initiative

Oorja, founded by Acceleron veterans, aims to innovate fibrosis treatments. This article explores the implications for the pharmaceutical industry.

Congressional Democrats Push to End Medicare AI Prior Authorization Pilot

Congressional Democrats are attempting to force a vote to terminate the Medicare AI prior authorization pilot. This move could have significant implications for the pharmaceutical industry.

Florida Hospitals Secure $8 Billion in Extra Medicaid Funds

Florida hospitals have secured $8 billion in additional Medicaid funding, significantly impacting the healthcare sector. This article explores the implications for pharmaceutical teams and investors.

CG Life's Strategic C-Suite Expansion: Collette Douaihy's Appointment

CG Life has appointed Collette Douaihy as Chief Creative Officer, marking a significant step in its C-suite expansion. This article explores the implications for the pharmaceutical sector.

Clinical Research Patient 2026: Key Insights and Expectations

As the Clinical Research Patient event approaches, industry professionals are eager to understand the implications for clinical trials and patient engagement. This coverage will highlight key insights and expectations for B2B readers.

Leadership Changes in Preventive Services Task Force: Implications for Pharma

Kennedy's recent decision to fire two leaders from the Preventive Services Task Force raises questions about future preventive health policies and their impact on the pharmaceutical sector.

Ebola: Perspectives from a Doctor and Patient

This article shares insights from a doctor who experienced Ebola firsthand, highlighting the need for greater awareness of the challenges faced by African healthcare workers.

Palvella's Pivotal Rare-Disease Data and Financial Outlook

Palvella (NASDAQ: PVLA) reveals pivotal data in rare diseases and boasts a robust cash runway of $274M, signaling significant investment potential.

Eli Lilly Acquires Engage to Boost Genetic Medicine Development

Eli Lilly's acquisition of Engage Bio marks a significant step in advancing non-viral genetic medicines. This article explores the implications for the pharmaceutical industry.

BBSW AI Solution 2026: Key Insights and Highlights

The BBSW AI Solution event in 2026 is set to unveil groundbreaking advancements in AI technology. Join us for live coverage and key insights from industry leaders.